CN

CN
Project
Target
Drug Modality
Disease Indication
Discovery
Preclinical
Development
Clinical
Trials(I-III)
Commercial
  • IPG11406
    EBI2 (GPR183)
    Small molecule antagonist
    · Autoimmune diseases(MS,IBD,RA,SLE/LN etc.)
    Global
  • IPG1094
    MIF
    Small molecular inhibitor
    · Solid Cancer
    · Ischemic stroke
    · Obesity ·
    Global
  • IPG7236
    CCR8
    Small molecule antagonist
    · Solid cancer
    · IgG4-related diseases
    Global
  • IPG0521
    CCR8
    mAb antagonist antibody with mild ADCC activity
    · Solid cancer
    · IgG4-related diseases
    Global
  • IPG8294
    CD38 NADase
    Small molecule inhibitor
    · Obesity/NASH
    · Mitochondrial myopathy
    · Alzheimer’s disease
    Global
  • IPG6620
    GPR92
    Small molecule antagonist
    · CIPN
    · Diabetic neuropathy
    Global
  • IPG0916
    CCR6
    mAb
    · Autoimmune diseases
    Global
Project
Target
Drug Modality
Disease Indication
Discovery
Preclinical
Development
Clinical
Trials(I-III)
Commercial
  • IPG11406
    EBI2 (GPR183)
    Small molecule antagonist
    · Autoimmune diseases(MS,IBD,RA,SLE/LN etc.)
    Global
  • IPG1094
    MIF
    Small molecular inhibitor
    · Solid Cancer
    · Ischemic stroke
    · Obesity ·
    Global
  • IPG7236
    CCR8
    Small molecule antagonist
    · Solid cancer
    · IgG4-related diseases
    Global
  • IPG0521
    CCR8
    mAb antagonist antibody with mild ADCC activity
    · Solid cancer
    · IgG4-related diseases
    Global
  • IPG8294
    CD38 NADase
    Small molecule inhibitor
    · Obesity/NASH
    · Mitochondrial myopathy
    · Alzheimer’s disease
    Global
  • IPG6620
    GPR92
    Small molecule antagonist
    · CIPN
    · Diabetic neuropathy
    Global
  • IPG0916
    CCR6
    mAb
    · Autoimmune diseases
    Global

Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd All Rights Reserved.